The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common lung ...

Launched in late 2015, sales of Nucala have been mounting and last quarter it generated sales of around £91 million. GSK has also filed Nucala with the FDA as a treatment for COPD. Analyst ...

GSK’s (LSE: GSK) biologic therapy Nucala (mepolizumab) has demonstrated a consistent reduction in exacerbation rates among patients with eosinophilic chronic obstructive pulmonary disease (COPD), ...

Credit: 1take1shot/Shutterstock. GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as an add-on maintenance treatment for the ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK announced on Thursday that its monoclonal antibody ‘Nucala’, or mepolizumab, delivered a statistically significant and clinically meaningful reduction in exacerbations for patients with ...